ETF Holdings Breakdown of VERV

Stock NameVerve Therapeutics Inc
TickerVERV(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS92539P1012

News associated with VERV

Invesco Ltd. Buys 3,080 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)
Invesco Ltd. raised its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 5.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 57,140 shares of the company’s stock after purchasing an additional 3,080 shares during the period. Invesco Ltd.’s holdings in Verve Therapeutics were worth $322,000 as of its most recent […] - 2025-05-05 07:38:47
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
Equity markets have been volatile this year due to macroeconomic and geopolitical factors. Many of the world's largest corporations haven't escaped the sell-off, and it's hard to predict what's next. Even so, Wall Street has high hopes for some companies. Take Verve Therapeutics - 2025-04-29 11:53:00
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Bank of Montreal Can
Bank of Montreal Can trimmed its stake in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 12.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,139 shares of the company’s stock after selling 6,131 shares during the quarter. Bank of Montreal Can owned about […] - 2025-04-25 07:36:51
Geode Capital Management LLC Increases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)
Geode Capital Management LLC increased its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,625,780 shares of the company’s stock after buying an additional 25,093 shares during the quarter. […] - 2025-04-24 07:58:47
Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $25.75 Average Price Target from Brokerages
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the […] - 2025-04-22 05:18:51
Verve Therapeutics (NASDAQ:VERV) Price Target Raised to $24.00
Verve Therapeutics (NASDAQ:VERV – Free Report) had its price objective increased by Guggenheim from $18.00 to $24.00 in a research report sent to investors on Tuesday morning, Marketbeat reports. Guggenheim currently has a buy rating on the stock. Other research analysts have also recently issued reports about the stock. William Blair reaffirmed an “outperform” rating […] - 2025-04-18 07:43:01
Verve Therapeutics (NASDAQ:VERV) Upgraded to Overweight at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Verve Therapeutics (NASDAQ:VERV – Free Report) from a neutral rating to an overweight rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. VERV has been the topic of several other research reports. Royal Bank of Canada lowered their price objective on Verve Therapeutics from $17.00 to […] - 2025-04-16 07:48:54
Verve Therapeutics (NASDAQ:VERV) Price Target Raised to $39.00 at Canaccord Genuity Group
Verve Therapeutics (NASDAQ:VERV – Free Report) had its target price upped by Canaccord Genuity Group from $32.00 to $39.00 in a research report report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock. A number of other analysts have also weighed in on VERV. HC Wainwright upped their price target on […] - 2025-04-16 07:48:52
Verve Therapeutics (NASDAQ:VERV) Price Target Raised to $25.00 at HC Wainwright
Verve Therapeutics (NASDAQ:VERV – Get Free Report) had its price objective raised by HC Wainwright from $15.00 to $25.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 403.02% from the company’s previous close. VERV has been […] - 2025-04-16 05:34:51
Pre-Market Most Active for Apr 14, 2025 : TSLL, KIDZ, NVDA, TQQQ, VERV, SQQQ, NIO, PFE, BABA, PG, DELL, TSM
The NASDAQ 100 Pre-Market Indicator is up 343.25 to 19,033.3. The total Pre-Market volume is currently 389,799,187 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.35 at $8.76, with 14,127,863 shar - 2025-04-14 12:29:57
KLP Kapitalforvaltning AS Buys Shares of 17,900 Verve Therapeutics, Inc. (NASDAQ:VERV)
KLP Kapitalforvaltning AS purchased a new position in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 17,900 shares of the company’s stock, valued at approximately $101,000. Other large investors also recently modified their holdings of the […] - 2025-04-11 08:39:05
Mitsubishi UFJ Asset Management Co. Ltd. Acquires 2,742 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)
Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 5.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,230 shares of the company’s stock after buying an additional 2,742 shares during the […] - 2025-04-04 08:12:55
Teacher Retirement System of Texas Has $114,000 Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)
Teacher Retirement System of Texas lifted its stake in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 37.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 20,254 shares of the company’s stock after acquiring an additional 5,512 shares during the quarter. Teacher […] - 2025-04-03 07:16:48
Verve Therapeutics (NASDAQ:VERV) Earns Buy Rating from HC Wainwright
Verve Therapeutics (NASDAQ:VERV – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 177.78% from the company’s previous close. Several other research […] - 2025-03-27 06:00:57
Guggenheim Reaffirms “Buy” Rating for Verve Therapeutics (NASDAQ:VERV)
Guggenheim restated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a report published on Tuesday,Benzinga reports. A number of other research analysts have also recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. HC […] - 2025-03-26 06:52:43
Bank of New York Mellon Corp Grows Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)
Bank of New York Mellon Corp increased its stake in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 2.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 220,502 shares of the company’s stock after acquiring an additional 5,262 shares during the quarter. Bank of New York Mellon Corp’s holdings in Verve Therapeutics […] - 2025-03-24 07:10:51
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down Following Analyst Downgrade
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report)’s share price gapped down prior to trading on Tuesday after Royal Bank of Canada lowered their price target on the stock from $17.00 to $15.00. The stock had previously closed at $6.17, but opened at $5.86. Royal Bank of Canada currently has an outperform rating on the […] - 2025-03-06 08:13:40
Verve Therapeutics (NASDAQ:VERV) Price Target Cut to $15.00 by Analysts at Royal Bank of Canada
Verve Therapeutics (NASDAQ:VERV – Get Free Report) had its target price lowered by equities researchers at Royal Bank of Canada from $17.00 to $15.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank of Canada’s target price would suggest a […] - 2025-03-06 07:27:08
Verve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, HC Wainwright Analyst Says
Verve Therapeutics (NASDAQ:VERV – Free Report) had its target price increased by HC Wainwright from $14.00 to $15.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock. A number of other equities analysts have also recently commented on the stock. Royal Bank of Canada decreased their […] - 2025-03-03 06:17:21
William Blair Reaffirms “Outperform” Rating for Verve Therapeutics (NASDAQ:VERV)
William Blair restated their outperform rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a research note published on Friday morning,RTT News reports. Several other equities research analysts also recently commented on the stock. HC Wainwright lowered their price objective on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” […] - 2025-02-24 06:46:54
China Universal Asset Management Co. Ltd. Buys 1,676 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)
China Universal Asset Management Co. Ltd. increased its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 10.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,952 shares of the company’s stock after buying an additional 1,676 shares during the period. China Universal […] - 2025-02-04 08:53:03

VERV institutional holdings

The following institutional investment holdings of VERV have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 58,637USD 262,694
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 113,041USD 506,424
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 43,359USD 194,248
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 43,359USD 194,248
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 3,111USD 13,937
Total =261,507 USD 1,171,551
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.